Aardvark Therapeutics, INC. 8-K Filing
Ticker: AARD · Form: 8-K · Filed: Sep 3, 2025 · CIK: 1774857
| Field | Detail |
|---|---|
| Company | Aardvark Therapeutics, INC. (AARD) |
| Form Type | 8-K |
| Filed Date | Sep 3, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Aardvark Therapeutics, INC. (ticker: AARD) to the SEC on Sep 3, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.00001 (ch registered Common Stock, par value $0.00001 per share AARD The Nasdaq Stock Mar).
How long is this filing?
Aardvark Therapeutics, INC.'s 8-K filing is 2 pages with approximately 470 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 470 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2025-09-02 20:56:36
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share AARD The Nasdaq Stock Mar
Filing Documents
- ck0001774857-20250902.htm (8-K) — 45KB
- ck0001774857-ex99_1.htm (EX-99.1) — 23KB
- ck0001774857-ex99_1s1.jpg (GRAPHIC) — 193KB
- ck0001774857-ex99_1s2.jpg (GRAPHIC) — 679KB
- ck0001774857-ex99_1s3.jpg (GRAPHIC) — 263KB
- ck0001774857-ex99_1s4.jpg (GRAPHIC) — 292KB
- ck0001774857-ex99_1s5.jpg (GRAPHIC) — 231KB
- ck0001774857-ex99_1s6.jpg (GRAPHIC) — 238KB
- ck0001774857-ex99_1s7.jpg (GRAPHIC) — 196KB
- ck0001774857-ex99_1s8.jpg (GRAPHIC) — 339KB
- ck0001774857-ex99_1s9.jpg (GRAPHIC) — 388KB
- ck0001774857-ex99_1s10.jpg (GRAPHIC) — 353KB
- ck0001774857-ex99_1s11.jpg (GRAPHIC) — 277KB
- ck0001774857-ex99_1s12.jpg (GRAPHIC) — 215KB
- ck0001774857-ex99_1s13.jpg (GRAPHIC) — 220KB
- ck0001774857-ex99_1s14.jpg (GRAPHIC) — 356KB
- ck0001774857-ex99_1s15.jpg (GRAPHIC) — 163KB
- ck0001774857-ex99_1s16.jpg (GRAPHIC) — 373KB
- ck0001774857-ex99_1s17.jpg (GRAPHIC) — 330KB
- ck0001774857-ex99_1s18.jpg (GRAPHIC) — 242KB
- ck0001774857-ex99_1s19.jpg (GRAPHIC) — 283KB
- ck0001774857-ex99_1s20.jpg (GRAPHIC) — 288KB
- ck0001774857-ex99_1s21.jpg (GRAPHIC) — 252KB
- ck0001774857-ex99_1s22.jpg (GRAPHIC) — 167KB
- 0000950170-25-112645.txt ( ) — 8911KB
- ck0001774857-20250902.xsd (EX-101.SCH) — 25KB
- ck0001774857-20250902_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On September 2, 2025, Aardvark Therapeutics, Inc. (the "Company") updated its corporate presentation for use in meetings from time to time with investors, analysts and others, which corporate presentation will also be posted to the Company's website. A copy of the corporate presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01. The presentation is current as of September 2, 2025, and the Company disclaims any obligation to update this material in the future.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Corporate Presentation, dated September 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AARDVARK THERAPEUTICS, INC. Date: September 2, 2025 By: /s/ Tien-Li Lee, M.D. Tien-Li Lee, M.D. Chief Executive Officer